Clinical Trials Logo
  1. Home
  2. NSCLC Stage IIIB
  3. NCT03231475

Phase I Study of SPH1188-11 in NSCLC — SPH1188-11  

NSCLC Stage IV Clinical Trial

Official title:
Phase I, Open-label Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of SPH1188-11 Tablets for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).

Clinical Trial Summary

This study will treat patients with advanced NSCLC who have already received at least one course of specific anti-cancer treatment but the tumour has started to re-grow following that treatment. This is the first time this drug has ever been tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment, it will measure the levels of drug in the body, it will also measure the anti-cancer activity. By using these pieces of information together the best dose of this drug to use in further clinical trials will be selected.

Clinical Trial Description

Phase I dose escalation study ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03231475
Study type Interventional
Source Shanghai Pharmaceuticals Holding Co., Ltd
Contact
Status Withdrawn
Phase Phase 1
Start date July 21, 2017
Completion date March 31, 2022
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05543330 - A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC Phase 1/Phase 2
Recruiting NCT04106180 - SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC Phase 2
Recruiting NCT05215548 - Primary Tumor Resection With EGFR TKI for Stage IV NSCLC Phase 2
Recruiting NCT04042558 - A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies Phase 2
Completed NCT04507217 - Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC Phase 2
Recruiting NCT04467801 - Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy Phase 2
Active, not recruiting NCT04027647 - Phase 2 Study of Dacomitinib in NSCLC Phase 2
Recruiting NCT04768491 - Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC
Not yet recruiting NCT04492969 - Prospective Observation of Failure Patterns in NSCLC Treated With ICIs
Recruiting NCT04116918 - Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC
Terminated NCT03411473 - Study of AGEN1884 With Pembrolizumab in 1L NSCLC Phase 2
Recruiting NCT03564197 - 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC N/A
Not yet recruiting NCT06219317 - Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC Phase 2
Not yet recruiting NCT04604470 - Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2
Recruiting NCT05132218 - Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer
Not yet recruiting NCT04136535 - Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC Phase 2
Completed NCT03184571 - Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC Phase 2
Completed NCT06339554 - Alectinib-induced Endocrine Toxicity
Recruiting NCT04549428 - Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC Phase 2
Recruiting NCT03647956 - Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors Phase 2